(HealthDay News) – Macrolide antibiotics are effective in reducing exacerbations in patients with non-cystic fibrosis bronchiectasis, although the resistance rate increases, according to two studies published in the March 27 issue of the Journal of the American Medical Association.
In the first study, Josje Altenburg, MD, from Medical Centre Alkmaar in the Netherlands, and colleagues randomly assigned 83 patients with non-cystic fibrosis bronchiectasis to placebo or 250mg daily azithromycin. After 12 months, the researchers found that the median number of exacerbations was significantly lower after azithromycin treatment (0 vs. 2). Azithromycin treatment also lowered the risk of having at least one exacerbation (46% vs. 80% of patients; hazard ratio, 0.29) but increased the macrolide resistance rate.
In the second study, David J. Serisier, MBBS, DM, from Mater Adult Hospital in South Brisbane, Australia, and colleagues randomly assigned 117 patients with non-cystic fibrosis bronchiectasis to placebo or 400mg erythromycin ethylsuccinate twice daily. After 12 months, the researchers found that erythromycin treatment significantly reduced the mean number of pulmonary exacerbations per patient per year (1.29 vs. 1.97). Erythromycin treatment also reduced 24-hour sputum production and attenuated lung function decline but increased the proportion of macrolide-resistant oropharyngeal streptococci.
“Macrolides offer an important and now evidence-based treatment for bronchiectasis and, if used carefully, may help to improve quality of life and reduce health care costs for patients with bronchiectasis,” write the authors of an accompanying editorial.
Teva supplied the azithromycin for the first study. The second study was funded by GlaxoSmithKline. Authors from both studies disclosed financial ties to the pharmaceutical industry.